Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420, a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.
November 23, 2020
· 5 min read